Levetiracetam

證據等級: L5

預測適應症: 10 個

drug.original_indications is empty and original_moa is [Data Gap], and taiwan_regulatory.licenses is empty (market_status = “未上市” / Not Marketed, 0 licenses) — so there is no TFDA-sourced original indication text to extract. I did not fabricate TFDA data; instead I grounded the “Original Indication” statement in the Evidence Pack’s own trial descriptions (e.g. NCT00203216: “levetiracetam is FDA approved as an add-on medication in the treatment of partial onset seizures in adults with epilepsy… trade name Keppra®”), and flagged the missing TFDA-specific record as Data Gap DG001.
Per the template’s explicit extraction rule, “Predicted New Indication” = predicted_indications[0], i.e. rank 1 “visual epilepsy” (score 0.9998, L2, Proceed with Guardrails) — not the strongest-evidence candidate in the list (rank 9 “status epilepticus” has L1/multiple RCTs), but the template instructs use of index 0, so the report follows that.
Cytotoxicity section omitted (levetiracetam is an antiepileptic, not antineoplastic).
Safety section collapsed to the fallback sentence since all safety fields are [Data Gap]/not found.

Levetiracetam: From Epilepsy to Visual Epilepsy

One-Sentence Summary

Levetiracetam is a broad-spectrum antiepileptic drug, established globally as add-on and monotherapy treatment for partial-onset seizures in patients with epilepsy. The TxGNN model predicts it may also be effective for Visual Epilepsy (a photosensitive/reflex epilepsy subtype), with 9 clinical trials and 20 publications currently identified in this evidence pack, though most of this evidence covers general epilepsy populations rather than the visually-induced subtype specifically.

Quick Overview

Item	Content
Original Indication	Epilepsy / partial-onset seizures (established global indication, per trial-reported labeling; Taiwan-specific TFDA approval record unavailable — see Data Gap DG001)
Predicted New Indication	Visual Epilepsy
TxGNN Prediction Score	99.98%
Evidence Level	L2
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (Data Gap DG002). Based on known information from the trial and literature records collected here, levetiracetam is a second-generation antiepileptic drug (marketed as Keppra®) whose established efficacy is in partial-onset seizures and, as adjunctive therapy, in myoclonic seizures of juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. Its pharmacology is generally understood to act via binding to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and dampening abnormal neuronal synchronization — this mechanistic description appears consistently across the collected literature even though a formal MOA field was not returned by DrugBank in this pack.

Visual epilepsy (photosensitive/visually-induced seizures) is classified as a reflex epilepsy and is closely related to idiopathic generalized epilepsy (IGE) with photosensitive features. Because reflex and generalized epilepsies share overlapping cortical hyperexcitability mechanisms with the partial-onset and generalized seizure types levetiracetam already treats, the TxGNN prediction is mechanistically plausible. However, as the repurposing rationale notes, the identified trials and literature largely evaluate levetiracetam in general epilepsy, neurocritical-care, or pediatric seizure populations rather than in visually-induced/photosensitive epilepsy specifically — supporting a cautious “Proceed with Guardrails” rather than a stronger recommendation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07336992	Phase 3	Not Yet Recruiting	580	Prophylactic levetiracetam for functional outcome in acute intracerebral haemorrhage; seizures occur in up to 40% of ICH patients within 7 days. Grade C relevance — ICH population, not reflex/photosensitive epilepsy.
NCT00203216	N/A	Completed	31	Open-label trial of levetiracetam for prophylactic treatment of migraine with/without visual aura. Grade C — general migraine prevention, not visual-epilepsy-specific.
NCT03107507	Phase 4	Unknown	40	Levetiracetam for control of neonatal seizures. Grade C — neonatal population, different mechanism.
NCT00855738	Phase 4	Completed	111	“Liceo” observational study of new AEDs (including levetiracetam) as first-line bitherapy for focal epilepsy. Grade B — may include reflex-epilepsy subgroups but not specific to them.
NCT04559529	Phase 2	Completed	62	Levetiracetam tested for reducing hippocampal hyperactivity in psychotic disorders using visual-scene-processing fMRI tasks. Grade C — psychiatric indication, not epilepsy.
NCT04833907	Phase 1/2	Enrolling by Invitation	24	Gene therapy (AVASPA) trial for Canavan Disease; not a levetiracetam efficacy trial. Grade C.
NCT04277936	Phase 2	Terminated	1	Same hippocampal-hyperactivity/psychosis design as NCT04559529; terminated with only 1 participant. Grade C — very weak evidence.
NCT04573803	Phase 3	Not Yet Recruiting	1649	MAST trial: AED duration/choice (levetiracetam vs phenytoin) for post-traumatic-brain-injury seizure prevention. Grade C — different etiology.
NCT00105040	Phase 2	Completed	87	19-week double-blind, placebo-controlled safety study of cognitive/neuropsychological effects of levetiracetam in children with refractory partial-onset seizures. Grade B — design may include photosensitive subgroups but not confirmed.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32385134	2020	RCT	Pediatrics	Levetiracetam vs phenobarbital for neonatal seizures — no FDA-approved therapy previously existed for this population; levetiracetam has proven efficacy/safety in older patients.
34286461	2022	Systematic Review/Meta-analysis	Neurocritical Care	Levetiracetam for seizure prophylaxis in neurocritical care (ICH, TBI, SAH); efficacy, optimal dosing and adverse events remain unclear.
40450767	2025	Systematic Review/Meta-analysis	Epilepsy & Behavior	Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy (including JME), compared with other ASMs for efficacy/safety.
37378757	2023	Systematic Review/Network Meta-analysis	Journal of Neurology	Antiseizure medications (including levetiracetam) for idiopathic generalized epilepsies — comparative efficacy and safety.
38316735	2024	Guideline	Neurocritical Care	Neurocritical Care Society clinical practice guideline for seizure prophylaxis in adults with moderate-severe TBI.
35963261	2022	Phase 3 RCT (PEACH trial)	The Lancet Neurology	Prophylactic levetiracetam to prevent epileptic seizures in acute intracerebral haemorrhage; double-blind, placebo-controlled.
38678766	2024	Comparative Study (open-label RCT)	Seizure	Phenytoin vs levetiracetam for acute symptomatic seizures in children with acute encephalitis syndrome.
34260837	2021	Review	New England Journal of Medicine	Initial management of seizure in adults.
35976303	2022	Review	Arquivos de Neuro-Psiquiatria	Status epilepticus: diagnosis, monitoring and treatment overview.
29037435	2018	Review (Veterinary)	Vet Clinics of North America: Small Animal Practice	Feline epilepsy management; notes levetiracetam may be useful for certain seizure types in cats.

US Market Information

Levetiracetam is currently recorded as Not Marketed in this regulatory dataset, with 0 license/NDA records returned. No product-level authorization data (dosage form, approved indication text) is available to populate a market information table. This should be independently verified against the official FDA Orange Book / NDA database, since the underlying TFDA/regulatory query in this evidence pack returned no results (query_log id 1, result_status: success, result_count: 0) rather than an explicit “not approved” determination.

Safety Considerations

Please refer to the package insert for safety information. (All safety fields in this evidence pack — key warnings, contraindications, and drug-drug interactions — returned no data; the DDI query status was “not_found”.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN model assigns a very high prediction score (99.98%) to visual epilepsy, and the mechanistic link (SV2A-mediated suppression of neuronal hyperexcitability, applicable to reflex/photosensitive epilepsy subtypes within the broader IGE spectrum) is plausible. However, the supporting clinical trial evidence (9 trials, evidence level L2) is drawn almost entirely from general epilepsy, neurocritical-care, or unrelated psychiatric populations rather than visual/photosensitive-epilepsy-specific studies — none of the identified trials directly enroll or report outcomes for this reflex subtype. This gap between a strong statistical signal and weak subtype-specific clinical evidence supports a guarded, evidence-gathering pathway rather than a full “Go.”

To proceed, the following is needed:

TFDA/FDA package insert (warnings, precautions, contraindications) — currently a Blocking data gap (DG001) that must be resolved before any S1 safety review can proceed.
Confirmed mechanism of action (MOA) data from DrugBank or equivalent source — currently a High-severity data gap (DG002) affecting mechanistic-relevance analysis.
A treatment-outcome-specific literature or trial search restricted to reflex/photosensitive epilepsy (rather than general epilepsy) to confirm whether levetiracetam’s benefit generalizes to this subtype.
Drug-drug interaction (DDI) data, since the current DDI query returned no results.
Confirmation of current US marketing/NDA status, since this dataset shows 0 license records despite levetiracetam (Keppra®) being a long-marketed drug in most regulatory jurisdictions — this discrepancy should be reconciled before relying on the “Not Marketed” status shown here.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.